American Society for Clinical Oncology (ASCO) 2024
ASCO recently held its 2024 conference from May 31-June 4, 2024. Click the links below to learn about MBC-related reports from this meeting.
Overview of MBC Results
- Living Beyond Breast Cancer (webinar): Rita Nanda, MD, provides updates about MBC from the 2024 ASCO annual meeting
Communicating with Your Care Team
- Breastcancer.org (podcast): A survey showed that poor communication between health care providers and patients can lead to worse understanding of information, patients being less likely to receive their recommended cancer treatments, and worse outcomes
- Living Beyond Breast Cancer: Cancer care, including supportive care, should be personalized according to both the tumor’s characteristics and the patient’s age and race/ethnicity
Results for People with HER2-Low or Ultralow MBC
- Living Beyond Breast Cancer: Results from the DESTINY-Breast06 trial showed that even people with MBC with very low levels of HER2, called ultralow, benefit from trastuzumab deruxtecan (T-Dxd; Enhertu®)
Results for People with Hormone Receptor-Positive, HER2-Negative MBC
- Living Beyond Breast Cancer: Results from the postMONARCH clinical trial showed that the combination of abemaciblib (Verzenio®) plus fulvestrant (Faslodex®) provides a modest benefit to people with hormone receptor-positive, HER2-negative MBC who have progressed on another CDK4/6 inhibitor
- Breastcancer.org: Results from the INAVO120 clinical trial showed that the combination of experimental PI3K inhibitor inavolisib, palbociclib (Ibrance®), and fulvestrant (Faslodex®) delays the time to receiving chemotherapy and provides a good quality of life and less pain in people with hormone receptor-positive, HER2-negative MBC with a PIK3CA mutation (scroll to “Experimental inavolisib doesn’t cause more side effects”)